TELA Bio CEO buys 12,500 shares at $0.66

Rhea-AI Filing Summary

TELA Bio, Inc. (TELA) director and Chief Executive Officer Heather C. Getz reported purchasing 12,500 shares of common stock on 2026-08-17 in an open-market or private transaction at a weighted average price of $0.6649 per share, with individual trade prices ranging from $0.6504 to $0.6749. Following this purchase, she directly owns 532,500 shares of TELA common stock.

Insider Trade Summary

Net Buyer: 12,500 shares

Net Buy 1 txn

Insider Getz Heather C

Role Chief Executive Officer

Bought 12,500 shs ($8K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1	12,500	$0.6649	$8K

Holdings After Transaction: Common Stock — 532,500 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6504 to $0.6749. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Key Figures

Shares Purchased: 12,500 shares Weighted Average Purchase Price: $0.6649 per share Post-Transaction Holdings: 532,500 shares +1 more

4 metrics

Shares Purchased 12,500 shares Common stock acquired by Heather C. Getz on 2026-08-17

Weighted Average Purchase Price $0.6649 per share Price for 12,500-share purchase of TELA common stock

Post-Transaction Holdings 532,500 shares Directly owned by Heather C. Getz after the reported transaction

Price Range of Purchases $0.6504–$0.6749 per share Range of individual trade prices within the reported purchase

Key Terms

weighted average price, open market or private transaction, Form 4

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction code description: Purchase in open market or private transaction"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TELA (TELA) report for Heather C. Getz?

Heather C. Getz reported buying 12,500 shares of TELA Bio, Inc. common stock on 2026-08-17. The transaction was coded as a purchase in an open-market or private transaction and increased her directly held position in the company.

At what price did Heather C. Getz buy TELA (TELA) shares?

She bought the shares at a weighted average price of $0.6649 per share. The filing notes the shares were acquired in multiple transactions at prices ranging from $0.6504 to $0.6749 during the purchase date.

How many TELA (TELA) shares does Heather C. Getz own after this transaction?

After the reported purchase, Heather C. Getz directly owns 532,500 shares of TELA Bio, Inc. common stock. This post-transaction holding reflects the addition of the newly purchased 12,500 shares to her prior direct ownership.

What does the Form 4 code P mean for the TELA (TELA) transaction?

Transaction code P on Form 4 indicates a purchase in an open market or private transaction. For TELA Bio, Inc., this means Heather C. Getz’s 12,500-share trade represents an acquisition rather than a sale or derivative-related exercise.

Was the TELA (TELA) insider purchase made under a Rule 10b5-1 plan?

The filing’s 10b5-1 checkbox is marked false, indicating the transaction was not affirmed as being made under a Rule 10b5-1 trading plan. No footnote describes the purchase as pre-arranged under such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/19/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Getz Heather C

(Last) (First) (Middle)

C/O TELA BIO, INC.

1 GREAT VALLEY PARKWAY, SUITE 24

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TELA Bio, Inc. [ TELA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		P		12,500	A	$0.6649(1)	532,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.6504 to $0.6749. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Megan Smeykal, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)